Roche licenses chronic pain program to start-up Afferent
Newly formed Afferent Pharmaceuticals has acquired exclusive rights to Roche's P2X3 antagonist program for chronic pain.
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.